Mundipharma enters distribution deal with Janssen

Janssen Pharmaceutica, part of  US healthcare giant Johnson & Johnson (NYSE: JNJ), has entered into an exclusive distribution agreement for diabetes treatments Invokana (canagliflozin) and Vokanamet (a fixed-dose combination of canagliflozin and metformin) in countries in the European Economic Area (EEA) and Switzerland where the products have obtained pricing and reimbursement approvals.

The agreement with UK-based Mundipharma became effective on August 21, 2017 in all concerned countries except in the UK and Italy where the agreement will become effective on September 16. Invokana received European Commission approval in November 2013. Additional EEA countries may be added to this agreement after gaining local pricing and reimbursement approvals.

As a result of this agreement, Mundipharma becomes the exclusive distributor for both products in the concerned countries, with exclusive rights to promote, distribute, and sell the products through its network of independent associated companies.